Cargando…
Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
BACKGROUND: Most SARS-CoV-2 infected patients develop IgG antibodies within 2–3 weeks after symptom onset. Antibody levels have been shown to gradually decrease in the first months after infection, but few data are available at six months or later. METHODS: A retrospective multi-center study was per...
Autores principales: | Van Elslande, Jan, Oyaert, Matthijs, Ailliet, Scott, Van Ranst, Marc, Lorent, Natalie, Vande Weygaerde, Yannick, André, Emmanuel, Lagrou, Katrien, Vandendriessche, Stien, Vermeersch, Pieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891078/ https://www.ncbi.nlm.nih.gov/pubmed/33636554 http://dx.doi.org/10.1016/j.jcv.2021.104765 |
Ejemplares similares
-
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
por: Van Elslande, Jan, et al.
Publicado: (2022) -
Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021) -
Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients
por: Van Elslande, J., et al.
Publicado: (2020) -
IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination
por: Van Elslande, Jan, et al.
Publicado: (2022) -
Analytical Performance of the RIDASCREEN(®) Hantavirus Puumala IgG/IgM ELISA Assay
por: Depypere, Melissa, et al.
Publicado: (2020)